FENNEC PHARMACEUTICALS INC. (FENC) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
27/62
2.2 / 5 stars
All 62 Win/Lose results and 58 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinFENC / S&P 74.80% / 15.20% |
WinFENC / S&P 77.83% / 15.00% |
LoseFENC / S&P -72.73% / 50.40% |
| 2026-Q11/3 |
LoseFENC / S&P -20.13% / -4.33% |
WinFENC / S&P 64.98% / 11.30% |
LoseFENC / S&P -47.17% / 27.70% |
| 2025-Q41/3 |
LoseFENC / S&P -17.74% / 2.65% |
LoseFENC / S&P -6.09% / 9.00% |
WinFENC / S&P 312.50% / 13.40% |
| 2025-Q32/3 |
WinFENC / S&P 12.77% / 8.12% |
LoseFENC / S&P -25.23% / 4.61% |
WinFENC / S&P 150.00% / 13.45% |
| 2025-Q21/3 |
WinFENC / S&P 36.29% / 10.94% |
LoseFENC / S&P -35.23% / 4.83% |
LoseFENC / S&P -1200.00% / 10.63% |
| 2025-Q11/3 |
WinFENC / S&P -3.64% / -4.27% |
LoseFENC / S&P -34.90% / 4.98% |
LoseFENC / S&P -1866.67% / 10.57% |
| 2024-Q42/3 |
WinFENC / S&P 26.40% / 2.41% |
WinFENC / S&P 99.89% / 5.25% |
LoseFENC / S&P -86.89% / 6.15% |
| 2024-Q30/2 |
LoseFENC / S&P -18.17% / 5.89% |
No dataFENC / S&P / 5.89% |
LoseFENC / S&P -86.84% / 6.11% |
| 2024-Q20/2 |
LoseFENC / S&P -45.05% / 4.28% |
No dataFENC / S&P / 5.38% |
LoseFENC / S&P -104.00% / 5.12% |
| 2024-Q10/2 |
LoseFENC / S&P -0.89% / 10.56% |
No dataFENC / S&P / 5.71% |
LoseFENC / S&P -103.06% / 5.59% |
| 2023-Q41/2 |
WinFENC / S&P 49.40% / 11.69% |
No dataFENC / S&P / 6.81% |
LoseFENC / S&P -31.46% / 7.78% |
| 2023-Q30/2 |
LoseFENC / S&P -14.95% / -3.27% |
No dataFENC / S&P / 7.52% |
LoseFENC / S&P -6.17% / -5.03% |
| 2023-Q21/2 |
LoseFENC / S&P 6.13% / 8.74% |
No dataFENC / S&P / 9.50% |
WinFENC / S&P 51.52% / -8.57% |
| 2023-Q11/2 |
LoseFENC / S&P -13.33% / 7.50% |
No dataFENC / S&P / 10.77% |
WinFENC / S&P 58.06% / -15.69% |
| 2022-Q42/2 |
WinFENC / S&P 18.52% / 7.56% |
No dataFENC / S&P / 11.88% |
WinFENC / S&P 34.85% / -17.99% |
| 2022-Q32/2 |
WinFENC / S&P 45.16% / -4.88% |
No dataFENC / S&P / 13.47% |
WinFENC / S&P 32.79% / -1.41% |
| 2022-Q21/2 |
WinFENC / S&P -0.36% / -16.10% |
No dataFENC / S&P / 13.71% |
LoseFENC / S&P -4.35% / 11.04% |
| 2022-Q11/2 |
WinFENC / S&P 27.27% / -4.60% |
No dataFENC / S&P / 15.97% |
LoseFENC / S&P -17.33% / 42.23% |
| 2021-Q40/2 |
LoseFENC / S&P -53.29% / 11.03% |
No dataFENC / S&P / 15.00% |
LoseFENC / S&P -13.16% / 96.40% |
| 2021-Q31/1 |
WinFENC / S&P 29.22% / 0.58% |
No dataFENC / S&P / 10.77% |
No dataFENC / S&P / 69.42% |
| 2021-Q21/1 |
WinFENC / S&P 17.39% / 8.55% |
No dataFENC / S&P / 6.58% |
No dataFENC / S&P / 51.81% |
| 2021-Q10/1 |
LoseFENC / S&P -16.64% / 6.17% |
No dataFENC / S&P / -1.06% |
No dataFENC / S&P / 7.39% |
| 2020-Q41/1 |
WinFENC / S&P 22.94% / 12.15% |
No dataFENC / S&P / -3.72% |
No dataFENC / S&P / -33.42% |
| 2020-Q30/1 |
LoseFENC / S&P -27.43% / 8.93% |
No dataFENC / S&P / -2.04% |
No dataFENC / S&P / -27.10% |
| 2020-Q21/1 |
WinFENC / S&P 40.57% / 20.54% |
No dataFENC / S&P / -0.46% |
No dataFENC / S&P / -27.11% |
| 2020-Q11/1 |
WinFENC / S&P -8.47% / -19.60% |
No dataFENC / S&P / 3.47% |
No dataFENC / S&P / -14.75% |
| 2019-Q41/1 |
WinFENC / S&P 34.93% / 9.07% |
No dataFENC / S&P / 5.36% |
No dataFENC / S&P / 2.99% |
| 2019-Q31/1 |
WinFENC / S&P 20.25% / 1.70% |
No dataFENC / S&P / 5.02% |
No dataFENC / S&P / 0.21% |
| 2019-Q20/1 |
LoseFENC / S&P -17.53% / 4.30% |
No dataFENC / S&P / 6.64% |
No dataFENC / S&P / 8.65% |
| 2019-Q10/1 |
LoseFENC / S&P -23.98% / 13.65% |
No dataFENC / S&P / 8.12% |
No dataFENC / S&P / 14.29% |
| 2018-Q40/1 |
LoseFENC / S&P -22.20% / -13.52% |
No dataFENC / S&P / 9.05% |
No dataFENC / S&P / 18.23% |
| 2018-Q30/1 |
LoseFENC / S&P -21.46% / 7.71% |
No dataFENC / S&P / 10.21% |
No dataFENC / S&P / 19.06% |
| 2018-Q20/1 |
LoseFENC / S&P -13.68% / 3.43% |
No dataFENC / S&P / 9.03% |
No dataFENC / S&P / 14.46% |
| 2018-Q11/1 |
WinFENC / S&P 20.71% / -0.76% |
No dataFENC / S&P / 7.68% |
No dataFENC / S&P / 12.46% |
| 2017-Q40/1 |
LoseFENC / S&P -9.65% / 6.64% |
No dataFENC / S&P / 7.03% |
No dataFENC / S&P / 13.82% |
| 2017-Q30/0 |
No dataFENC / S&P / 4.48% |
No dataFENC / S&P / 5.68% |
No dataFENC / S&P / 17.57% |
| 2017-Q20/0 |
No dataFENC / S&P / 3.09% |
No dataFENC / S&P / 4.83% |
No dataFENC / S&P / 17.74% |
| 2017-Q10/0 |
No dataFENC / S&P / 6.07% |
No dataFENC / S&P / 3.67% |
No dataFENC / S&P / 13.32% |
| 2016-Q40/0 |
No dataFENC / S&P / 3.82% |
No dataFENC / S&P / 2.09% |
No dataFENC / S&P / 7.05% |
| 2016-Q30/1 |
No dataFENC / S&P / 3.85% |
No dataFENC / S&P / 0.20% |
LoseFENC / S&P -258.33% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | FENC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 32.69% | 20.78% |
| Annualized return | 32.69% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | FENC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 49.75% | 83.14% |
| Annualized return | 8.41% | 12.86% |
10Y · 2017-09-15 to 2026-08-27
| Metric | FENC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -1.92% | 319.30% |
| Annualized return | -0.19% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |